Clinical Evaluation of SON-1010 Dose Escalation Expanded with Atezolizumab in Ovarian Cancer
“The primary goal for the first part of this study was to establish the maximum dose of SON-1010 in combination with atezolizumab as an immune checkpoint inhibitor (ICI), and to provide better evidence of efficacy in the expansion group,” said Raghu Rao, Sonnet’s Interim Chief Executive Officer. “We will follow the patients currently being treated at the E6 dose to assess longer-term safety and tumor responses, and look forward to studying a 25% higher dose in the E7 cohort before selecting the best dose and moving to Part 2. Sonnet continues to seek partnership opportunities to help support the later stage development of SON-1010.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us